Nephros, Inc. (NEPH)
NEPH · BiotechSign PipelinePipeline Overview
- Therapeutic Focus
- Nephrologysrc
Signal Snapshot
0
Clinical Trials (ClinicalTrials.gov aggregate)
0
Catalyst Records
2
Publications on Record
ClinicalTrials.gov aggregate as of 2026-09-29. Source
Recent Publications
- Effects of a 16-week physical training on clinical outcomes in patients with hypertension and chronic kidney disease: NEPHROS post-trial follow-up. — Cad Saude Publica (2022) PMID 35584433
- The effects of an ACE inhibitor and a calcium antagonist on the progression of renal disease: the Nephros Study. — Nephrol Dial Transplant (2001) PMID 11682661
Get real-time catalyst alerts, analyst signals, dilution risk scores, and full pipeline data for Nephros, Inc..
Full NEPH Data Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.